Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Research Report - Global Forecast till 2027

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Information By Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis (Plasma Exchange), Physiotherapy, Others), Diagnosis (Electrodiagnostic Testing, Nerve Conduction, EMG, Spinal Fluid Analysis, Others), By Route of Administration (Intravenous, Oral, Others), By End User (Hospitals, Specialty Neurological Clinics, Research & Academic Laboratories, Others) and Top Regions Forecast till 2027.

ID: MRFR/HC/5482-CR | December 2018 | Region: Global | 124 pages

Chronic Inflammatory Demyelinating Polyneuropathy Market Snapshots


Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological autoimmune disorder where myelin, an essential part of the nervous system is being attacked by the body's immune system. It is a medical condition where the body's immune system fails to differentiate between own cells and foreign cells and starts attacking its healthy cells. As per the analysis of Market Research Future (MRFR), the chronic inflammatory demyelinating polyneuropathy market is aiming for a CAGR of 6.2% and is due to reach USD 3907.17 Mn by the end of the forecast period of 2018-2023. The chronic inflammatory demyelinating polyneuropathy market stood at USD 2723.42 Mn in 2017.


There has been a spiraling rise in the prevalence of autoimmune disorders in the recent past which offers scope for the growth of the global chronic inflammatory demyelinating polyneuropathy disease market. Patients suffering from autoimmune disorders are more likely to suffer from the disease. Growing incidences of CIDP has evoked major concern within the medical sector, especially in the developed countries. Various public, as well as private organizations, have undertaken initiatives for R&D activities which has yielded positive outcomes in the CIDP space. Noteworthy results have been achieved through rigorous R&D efforts and clinical trials. Various new drugs have been launched into the market after recent FDA approvals which also boosts the growth of the chronic inflammatory demyelinating polyneuropathy market. Other factors encouraging the growth of the market include surging awareness about the disease and government endeavors regarding the same.


the downside, the high cost of Intravenous immunoglobulin treatment and the side effects accompanied with its administration such as hypotension, nausea, lower back pain, flushing, chills, wheezing, etc. remain hindrance to the growth of the market. Meanwhile, high unmet need for advanced treatment options for the disease is likely to bring to view new opportunities for market players over the forecast period.


Chronic Inflammatory Demyelinating Polyneuropathy Market Players Covered


Bio Products Laboratory Ltd., Momenta Pharmaceuticals, Grifols, Baxter, Kedrion S.p.A, Octapharma, Shire, Mitsubishi Tanabe Pharma Corporation, CSL Behring,Teijin Pharma Limited, Pfizer, Inc. are the key players in the chronic inflammatory demyelinating polyneuropathy market. Segmental Analysis By Treatment & Diagnosis



  • TreatmentIntravenous Immunoglobulin

  • Corticosteroids

  • Plasmapheresis (plasma exchange)

  • Physiotherapy

  • Others

  • Diagnosis

  • Electrodiagnostic Testing

  • Nerve Conduction

  • EMG

  • Spinal Fluid Analysis

  • Others


By Route of Administration



  • Intravenous

  • Oral

  • Others


By End User



  • Hospitals

  • Specialty Neurological Clinics

  • Research & Academic Laboratories

  • Others


Chronic Inflammatory Demyelinating Polyneuropathy Market Report Overview


This MRFR report provides a forward-looking perspective on the different factors influencing the growth of the Chronic inflammatory demyelinating polyneuropathy market. Drivers, restraints, opportunities, challenges and other factors are discussed in detail to promote a deeper understanding of the market dynamics. The report covers a detailed profile of key players, their market share, geographical presence, strategies adopted by them and changing competition dynamics. Various treatment methods such as intravenous immunoglobulin, corticosteroids, plasmapheresis, physiotherapy, and others are covered.  The diverse end user segments included in the report are hospitals, specialty neurological clinics, research & academic laboratories, and others.  The report analyzes the key competencies of key players and provides insights into the strategies adopted by them to gain an edge over the market. Geographical presence of each player, their market share, country-level analysis and revenue forecast for each segment has also been provided in the report.


Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, by Region



  • Americas



  • US

  • Canada




    • North America

    • Latin America


  • Europe



  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe




    • Western Europe

    • Eastern Europe


  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • The Middle East & Africa


    • Middle East

    • Africa



Research Methodology


MRFR provides thoroughly studied market reports by combining the right mix of primary and secondary research methods, to aid clients to achieve their business goals. MRFR's research modules are designed with a specialized approach to meet industry-specific standards. A skilled team of analyst employs primary research techniques such as questionnaires, interviews, and personal interaction with key level market participants to collect valuable information about the market. Data collected from secondary sources such as white papers, annual reports, company websites, paid databases are combined with primary data to provide high-quality, accurate, and unbiased results.



Speak to Analyst Ask for Customization

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disorder that causes the immune system of the body to attack the myelin, which is an important part of the nervous system. Chronic inflammatory demyelinating polyneuropathy is a growing market as per the analysis of Market Research Future (MRFR). According to the report, the global chronic inflammatory demyelinating polyneuropathy market has been projected to reach the USD 3907.17 million marks at a CAGR of 6.2% over the forecast period of 2017-2023.


Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market has experienced witnessed substantial growth over the last few years due to the demand from the medical sector and growing awareness about the hazard it can be.


Increasing awareness about Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), increasing research and development (R&D) related to plasma-derived medicines, and the rising prevalence of autoimmune diseases. The market for CIDP can grow as it enables advanced treatment for this disorder and makes it more accessible. However, side-effects associated with the Intravenous Immunoglobulin (IVIG) treatment and the high cost of IVIG treatment can hinder market growth.


The Global Chronic Inflammatory Demyelinating Polyneuropathy Market has been segmented on the basis of end users, route of administration, treatment & diagnosis, and lastly region.


Based on end users, this market has been segmented into hospitals, research & academic laboratories, specialty neurological clinics, and others. Hospitals segment is likely to witness the highest growth at 6.28% CAGR during the forecast period.


Regarding the route of administration, the market has been segmented into intravenous, oral, and others. The intravenous segment is expected to witness the highest growth at 6.46% CAGR during the forecast period.


On the basis of treatment & diagnosis, the market has been segmented into the market has been segmented into diagnosis and treatment. Treatment segment is expected to witness the highest growth at 6.32% CAGR during the forecast period.


Regional Analysis


The regional segmentation of the Chronic inflammatory demyelinating polyneuropathy market covers regions such as The Americas (North America & South America), Europe, Asia Pacific, and the Middle East & Africa (MEA). The Asia Pacific is anticipated to be the fastest growing regional market. It has been anticipated to witness huge growth at 7.03% CAGR due to rapid urbanization, steadily rising technological advancement, and improving medical facilities. The pivotal country-specific markets in this region are Australia, China, India, Japan, and South Korea, followed by the remaining countries of the Asia Pacific region. China is the fastest growing market in this region, growing at 7.84% CAGR. Its worth by the end of forecast period has been estimated to be USD 192.42 million.


The Americas is the largest regional market with 52% of global share. In 2017, its value was USD 1415.96 million. During the forecast period, it may grow at a 5.90% CAGR with the worth of USD 1997.30 million. In this region, North America is a bigger market than South America due to the already established medical sector, advanced technology, and more awareness regarding CIDP. During the forecast period, the North American market is likely to witness faster growth compared to the South American market with 6.23% CAGR, and its worth is expected to be USD 1667.62 million. USA and Canada are the significant country-specific markets in this region. In this region, advanced medical facilities and higher purchasing power of patients and potential patients contribute to the market growth. The USA is the largest country-specific market in this region which is expected to grow at 6.48% CAGR by the end of the forecast period, and its worth has been estimated at USD 1352.99 million.


Europe is the second largest regional market. The pivotal country-specific markets in this region are Germany, France, Italy, Russia, Spain, and the UK, followed by the remaining countries of Western Europe and then Eastern Europe. Major factor aiding the market growth in this region is technological advancement second only to North America and advanced medical facilities. Due to both of these factors, Western Europe is a bigger market than Eastern Europe. The market growth for Europe is expected to register growth at 6.47% CAGR during the forecast period. Italy is likely to witness the highest growth in Europe at 7.75% CAGR during the forecast period.


In the MEA region, the market is limited to due to lack of education, lack of awareness, lack of advanced medical facilities, and limited availability of advanced technology. Overall market growth during the forecast period has been estimated to be The Middle East market is bigger than the African market. During the forecast period, the Middle East market is expected to grow at 5.08% CAGR.


Competitive Tracking


Baxter, Bio Products Laboratory Ltd., CSL Behring, Grifols, Kedrion S.P.A, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Octapharma, Pfizer Inc, Shire, and Teijin Pharma Limited.

1 Report Prologue

2 Executive Summary

3 Market Introduction

3.1 Definition 21

3.2 Scope of the Study 21

3.3 Research Objective 21

3.4 Assumptions & Limitations 21

3.4.1 Assumptions 21

3.4.2 Limitations 21

3.5 Market Structure 22

4 Research Methodology

4.1 Research Process 24

4.2 Primary Research 25

4.3 Secondary Research 26

4.4 Market Size Estimation 27

4.5 Forecast Model 27

5 Market Dynamics

5.1 Introduction 29

5.2 Drivers 30

5.2.1 Rising prevalence of autoimmune diseases 30

5.2.2 Increasing research and development related to plasma-derived medicines 30

5.2.3 Increasing awareness about Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 30

5.3 Restraints 31

5.3.1 Side-effects associated with the Intravenous Immunoglobulin (IVIG) treatment 31

5.3.2 High cost of the IVIG treatment 31

5.4 Opportunity 31

5.4.1 Advancements in the treatment 31

5.5 Clinical Trials Data 32

6 Market Factor Analysis

6.1 Porter’s Five Forces Model 34

6.1.1 Bargaining Power of Suppliers 34

6.1.2 Bargaining Power of Buyers 34

6.1.3 Threat of New Entrants 35

6.1.4 Threat of Substitutes 35

6.1.5 Intense Rivalry 35

6.2 Supply Chain Analysis 36

6.2.1 R&D and Designing 36

6.2.2 Manufacturing 36

6.2.3 Distribution & Sales 36

6.2.4 Post-Sales Monitoring 36

7 Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

7.1 Introduction 38

7.2 Treatment 41

7.3 Diagnosis 41

8 Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

8.1 Introduction 43

8.2 Intravenous 44

8.3 Oral 44

9 Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

9.1 Introduction 46

9.2 Hospitals 47

9.3 Specialty Neurological Clinics 47

9.4 Research & Academic Laboratories 48

10 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Region

10.1 Introduction 50

10.2 Americas 52

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.2.1 North America 55

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.2.1.1 U.S. 57

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.2.1.2 Canada 59

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.2.2 South America 61

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3 Europe 64

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3.1 Western Europe 67

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3.1.1 Germany 70

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3.1.2 France 72

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3.1.3 U.K 74

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3.1.4 Italy 76

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3.1.5 Spain 78

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3.1.6 Rest of Western Europe 80

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.3.2 Eastern Europe 82

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.4 Asia Pacific 84

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.4.1 China 87

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.4.2 Japan 89

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.4.3 India 91

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.4.4 Australia 93

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.4.5 Republic of Korea 95

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.4.6 Rest of Asia Pacific 97

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.5 Middle East and Africa 99

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.5.1 Middle East 102

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

10.5.2 Africa 104

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis

Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User

11 Competitive Landscape

11.1 Company Market Share Analysis 107

11.2 Introduction 107

12 Company Profiles

12.1 Grifols 110

12.1.1 Company Overview 110

12.1.2 Financial Overview 110

12.1.3 Products/Services Offered 111

12.1.4 SWOT Analysis 111

12.1.5 Key Developments 111

12.1.6 Key strategy 111

12.2 Shire 112

12.2.1 Company Overview 112

12.2.2 Financial Overview 112

12.2.3 Products/Services Offered 113

12.2.4 SWOT Analysis 113

12.2.5 Key Developments 113

12.2.6 Key strategy 113

12.3 Baxter 114

12.3.1 Company Overview 114

12.3.2 Company Overview 114

12.3.3 Products/Services Offered 115

12.3.4 SWOT Analysis 115

12.3.5 Key Developments 115

12.3.6 Key strategy 115

12.4 Pfizer, Inc. 116

12.4.1 Company Overview 116

12.4.2 Financial Overview 116

12.4.3 Products/Services Offered 117

12.4.4 SWOT Analysis 117

12.4.5 Key Developments 117

12.4.6 Key Strategy 117

12.5 CSL Behring 118

12.5.1 Company Overview 118

12.5.2 Financial Overview 118

12.5.3 Products/Services Offered 119

12.5.4 SWOT Analysis 119

12.5.5 Key Developments 119

12.5.6 Key Strategy 120

12.6 Kedrion S.p.A 121

12.6.1 Company Overview 121

12.6.2 Financial Overview 121

12.6.3 Products/Services Offered 122

12.6.4 SWOT Analysis 122

12.6.5 Key Development 122

12.6.6 Key Strategy 122

12.7 Octapharma 123

12.7.1 Company Overview 123

12.7.2 Financial Overview 123

12.7.3 Products/Services Offered 123

12.7.4 SWOT Analysis 124

12.7.5 Key Development 124

12.7.6 Key Strategy 124

12.8 Momenta Pharmaceuticals 125

12.8.1 Company Overview 125

12.8.2 Financial Overview 125

12.8.3 Products/Services Offered 126

12.8.4 SWOT Analysis 126

12.8.5 Key Development 126

12.8.6 Key Strategy 126

12.9 Teijin Pharma Limited 127

12.9.1 Company Overview 127

12.9.2 Financial Overview 127

12.9.3 Products/Services Offered 128

12.9.4 SWOT Analysis 128

12.9.5 Key Developments 128

12.9.6 Key strategy 128

12.10 Mitsubishi Tanabe Pharma Corporation 129

12.10.1 Company Overview 129

12.10.2 Financial Overview 129

12.10.3 Products/Services Offered 130

12.10.4 SWOT Analysis 130

12.10.5 Key Developments 130

12.11 Bio Products Laboratory Ltd. 131

12.11.1 Company Overview 131

12.11.2 Financial Overview 131

12.11.3 Products/Services Offered 131

12.11.4 SWOT Analysis 131

12.11.5 Key Developments 131

12.11.6 Key strategy 131

13 Appendix

13.1 Discussion Blue Print 133

14 List of Tables

TABLE 1 MARKET SYNOPSIS 19

TABLE 2 PRIMARY INTERVIEWS 24

TABLE 3 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 39

TABLE 4 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 40

TABLE 5 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 40

TABLE 6 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 40

TABLE 7 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY REGION,

2020-2027 (USD MILLION) 41

TABLE 8 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY REGION,

2020-2027 (USD MILLION) 41

TABLE 9 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 44

TABLE 10 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR INTRAVENOUS BY REGION,

2020-2027 (USD MILLION) 44

TABLE 11 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ORAL BY REGION,

2020-2027 (USD MILLION) 44

TABLE 12 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY END USER, 2020-2027 (USD MILLION) 47

TABLE 13 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR HOSPITALS, BY REGION,

2020-2027 (USD MILLION) 47

TABLE 14 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR SPECIALTY NEUROLOGICAL CLINICS,

BY REGION, 2020-2027 (USD MILLION) 47

TABLE 15 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR RESEARCH & ACADEMIC

LABORATORIES, BY REGION, 2020-2027 (USD MILLION) 48

TABLE 16 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2020-2027 (USD MILLION) 51

TABLE 17 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2020-2027 (USD MILLION) 52

TABLE 18 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 52

TABLE 19 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 53

TABLE 20 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 53

TABLE 21 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 53

TABLE 22 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 54

TABLE 23 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 54

TABLE 24 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY,

2020-2027 (USD MILLION) 55

TABLE 25 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET,

BY TREATMENT & DIAGNOSIS, 2020-2027 (USD MILLION) 55

TABLE 26 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2020-2027 (USD MILLION) 55

TABLE 27 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2020-2027 (USD MILLION) 56

TABLE 28 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2020-2027 (USD MILLION) 56

TABLE 29 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2020-2027 (USD MILLION) 56

TABLE 30 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 57

TABLE 31 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 57

TABLE 32 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 57

TABLE 33 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 58

TABLE 34 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 58

TABLE 35 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 58

TABLE 36 U. S. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 59

TABLE 37 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 59

TABLE 38 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 59

TABLE 39 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 60

TABLE 40 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 60

TABLE 41 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 60

TABLE 42 CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 61

TABLE 43 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2020-2027 (USD MILLION) 61

TABLE 44 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 61

TABLE 45 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 62

TABLE 46 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2020-2027 (USD MILLION) 62

TABLE 47 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2020-2027 (USD MILLION) 62

TABLE 48 SOUTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 63

TABLE 49 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2020-2027 (USD MILLION) 64

TABLE 50 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 64

TABLE 51 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 65

TABLE 52 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 65

TABLE 53 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 65

TABLE 54 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 66

TABLE 55 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 66

TABLE 56 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY,

2020-2027 (USD MILLION) 67

TABLE 57 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2020-2027 (USD MILLION) 67

TABLE 58 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2020-2027 (USD MILLION) 68

TABLE 59 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2020-2027 (USD MILLION) 68

TABLE 60 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2020-2027 (USD MILLION) 68

TABLE 61 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2020-2027 (USD MILLION) 69

TABLE 62 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 69

TABLE 63 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 70

TABLE 64 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 70

TABLE 65 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 70

TABLE 66 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 71

TABLE 67 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 71

TABLE 68 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 71

TABLE 69 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 72

TABLE 70 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

\2020-2027 (USD MILLION) 72

TABLE 71 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 72

TABLE 72 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 73

TABLE 73 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 73

TABLE 74 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 73

TABLE 75 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 74

TABLE 76 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 74

TABLE 77 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 74

TABLE 78 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 75

TABLE 79 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 75

TABLE 80 U.K CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 75

TABLE 81 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 76

TABLE 82 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 76

TABLE 83 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 76

TABLE 84 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 77

TABLE 85 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 77

TABLE 86 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 77

TABLE 87 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 78

TABLE 88 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 78

TABLE 89 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 78

TABLE 90 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 79

TABLE 91 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 79

TABLE 92 SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 79

TABLE 93 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET,

BY TREATMENT & DIAGNOSIS, 2020-2027 (USD MILLION) 80

TABLE 94 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

TREATMENT BY TYPE, 2020-2027 (USD MILLION) 80

TABLE 95 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

DIAGNOSIS BY TYPE, 2020-2027 (USD MILLION) 80

TABLE 96 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

ELECTRODIAGNOSTIC TESTING BY TYPE, 2020-2027 (USD MILLION) 81

TABLE 97 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET,

BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 81

TABLE 98 REST OF WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 81

TABLE 99 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2020-2027 (USD MILLION) 82

TABLE 100 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2020-2027 (USD MILLION) 82

TABLE 101 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2020-2027 (USD MILLION) 82

TABLE 102 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2020-2027 (USD MILLION) 83

TABLE 103 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2020-2027 (USD MILLION) 83

TABLE 104 EASTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 83

TABLE 105 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY,

2020-2027 (USD MILLION) 84

TABLE 106 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2020-2027 (USD MILLION) 84

TABLE 107 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 85

TABLE 108 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 85

TABLE 109 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2020-2027 (USD MILLION) 85

TABLE 110 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 86

TABLE 111 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 86

TABLE 112 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 87

TABLE 113 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 87

TABLE 114 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 87

TABLE 115 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 88

TABLE 116 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 88

TABLE 117 CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 88

TABLE 118 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 89

TABLE 119 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 89

TABLE 120 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 89

TABLE 121 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 90

TABLE 122 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 90

TABLE 123 JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 90

TABLE 124 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 91

TABLE 125 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 91

TABLE 126 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 91

TABLE 127 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 92

TABLE 128 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 92

TABLE 129 INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 92

TABLE 130 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 93

TABLE 131 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 93

TABLE 132 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 93

TABLE 133 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 94

TABLE 134 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 94

TABLE 135 AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 94

TABLE 136 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2020-2027 (USD MILLION) 95

TABLE 137 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2020-2027 (USD MILLION) 95

TABLE 138 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 95

TABLE 139 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

ELECTRODIAGNOSTIC TESTING BY TYPE, 2020-2027 (USD MILLION) 96

TABLE 140 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2020-2027 (USD MILLION) 96

TABLE 141 REPUBLIC OF KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 96

TABLE 142 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2020-2027 (USD MILLION) 97

TABLE 143 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2020-2027 (USD MILLION) 97

TABLE 144 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2020-2027 (USD MILLION) 97

TABLE 145 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

ELECTRODIAGNOSTIC TESTING BY TYPE, 2020-2027 (USD MILLION) 98

TABLE 146 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF

ADMINISTRATION, 2020-2027 (USD MILLION) 98

TABLE 147 REST OF ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 98

TABLE 148 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION,

2020-2027 (USD MILLION) 99

TABLE 149 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT &

DIAGNOSIS, 2020-2027 (USD MILLION) 99

TABLE 150 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT

BY TYPE, 2020-2027 (USD MILLION) 100

TABLE 151 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS

BY TYPE, 2020-2027 (USD MILLION) 100

TABLE 152 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR

ELECTRODIAGNOSTIC TESTING BY TYPE, 2020-2027 (USD MILLION) 100

TABLE 153 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 101

TABLE 154 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 101

TABLE 155 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 102

TABLE 156 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 102

TABLE 157 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 102

TABLE 158 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC

TESTING BY TYPE, 2020-2027 (USD MILLION) 103

TABLE 159 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 103

TABLE 160 MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS,

2020-2027 (USD MILLION) 103

TABLE 161 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020-2027 (USD MILLION) 104

TABLE 162 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE,

2020-2027 (USD MILLION) 104

TABLE 163 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE,

2020-2027 (USD MILLION) 104

TABLE 164 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING

BY TYPE, 2020-2027 (USD MILLION) 105

TABLE 165 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020-2027 (USD MILLION) 105

TABLE 166 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2020-2027 (USD MILLION) 105


15 List of Figures

FIGURE 1 RESEARCH PROCESS 24

FIGURE 2 TOP-DOWN & BOTTOM-UP APPROACH 27

FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

(CIDP) MARKET 29

FIGURE 4 PORTER’S FIVE FORCES ANALYSIS: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET 34

FIGURE 5 SUPPLY CHAIN: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET 36

FIGURE 6 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY TREATMENT & DIAGNOSIS,

2020 (%) 39

FIGURE 7 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS,

2020 & 2027 (USD MILLION) 39

FIGURE 8 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY ROUTE OF

ADMINISTRATION, 2020 (%) 43

FIGURE 9 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION,

2020 & 2027 (USD MILLION) 43

FIGURE 10 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY END USER, 2020 (%) 46

FIGURE 11 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USER, 2020 & 2027 (USD MILLION) 46

FIGURE 12 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2020 & 2027 (USD MILLION) 50

FIGURE 13 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2020 (%) 51

FIGURE 14 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2020 (%) 52

FIGURE 15 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2020 (%) 64

FIGURE 16 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY COUNTRY, 2020 (%) 67

FIGURE 17 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY COUNTRY, 2020 (%) 84

FIGURE 18 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE,

BY COUNTRY, 2020 (%) 99

FIGURE 19 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) MARKET SHARE ANALYSIS 2020 (%) 107



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.

Numerous players are operating in the Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market. Some of the big players have captured a significant share in the global market, taking advantage of their strong position and presence in the number of countries and regions across the world.


The top players in the global chronic inflammatory demyelinating polyneuropathy (CIDP) market are Grifols, CSL Behring, Shire, Octapharma, and Kedrion S.p.A. Grifols held the first position in the global chronic inflammatory demyelinating polyneuropathy (CIDP) market with a 25.9% market share in 2017. It is one of the largest and fastest growing market players in the plasma-derived medicines market. The company has a strong presence in the Americas and Europe, but when it comes to Asia-Pacific and the Middle Eastern and African region, its presence is negligible. Grifols had been showing a constant growth in revenues from the last three years. In terms of profitability, the bioscience segment is contributing the maximum.


CSL Behring accounted for the second-largest market share of 23.4% in 2017. CSL has a strong presence in the global market, and its financial condition is stable as compared to other market players. The net profit of the company was USD 1,337 million during 2016 to2017 and USD 1,729 million from 2017 to 2018. The company paid a dividend of USD 1.2 per share for 2017 to 2018. CSL is investing huge money in R&D, and the approval of the Food and Drug Administration (FDA) for Hizentra for the treatment of CIDP can provide favorable conditions for the company to strengthen its position in the global chronic inflammatory demyelinating polyneuropathy (CIDP) market.


Shire holds a strong position in the rare diseases market. The company is likely to show a double-digit compound annual top-line growth during the forecast period owing to the acquisition of Baxalta from Baxter group. The revenue of shire increased from USD 6,416.7 million to USD 11,397 million after the acquisition Baxalta. Shire is running 50 clinical development programs in 100 countries which will help the company to generate maximum revenue in the future. The company accounted for 20.5% of the total market share in 2017.


Octapharma holds the fourth largest position in the global chronic inflammatory demyelinating polyneuropathy (CIDP) market with a market share of 8.5%. It has a strong distribution network of plasma collection centers in more than 95 countries. Ongoing research and development activities and product approvals are going to help Octapharma to increase its market share in the global chronic inflammatory demyelinating polyneuropathy (CIDP) market.


Kedrion S.p.A is into research and development of treatment for rare diseases. The company offers services related to contract research and manufacturing. The company also outsources manufacturing services from other market players. Currently, the company is outsourcing manufacturing services from Grifols Therapeutics Inc for Gammaked. It holds the fifth largest position in the global chronic inflammatory demyelinating polyneuropathy (CIDP) market with a market share of 2.4%.